J&J Ollin Acquisition: $2.2B Bet on an Eye Drug Built to Beat Vabysmo
J&J will pay $2.2B upfront for Ollin Biosciences and its VEGF/Ang2 eye drug OLN324, with Blackstone funding $750M of Phase 3. Terms, science and risks.
J&J will pay $2.2B upfront for Ollin Biosciences and its VEGF/Ang2 eye drug OLN324, with Blackstone funding $750M of Phase 3. Terms, science and risks.